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Background
Despite years of experience with vitamin K antagonist-associated bleeding events, there is still
no evidence to help identify the optimal treatment with prothrombin complex concentrates.
Variable dosing and fixed dose strategies are being used. In this observational prospective two-
cohort study, we aimed to assess the non-inferiority of a low fixed PCC dose (1,040 IU Factor
IX) compared to the registered variable dosing regimen based on baseline International
Normalized Rate, bodyweight, and target International Normalized Rate, to counteract vitamin
K antagonists in a bleeding emergency in a daily clinical practice setting.  
Design and Methods
Non-inferiority of the fixed prothrombin complex concentrate dose was hypothesized with a
margin of 4%. Main end points were proportion of patients reaching the target International
Normalized Rate (< 2.0) after prothrombin complex concentrate treatment, and successful clin-
ical outcome.  
Results
Target International Normalized Rate was reached in 92% of the fixed dose patients (n=101)
versus 95% of variable dose patients (n=139) resulting in a risk difference of -2.99% (90% CI: -
8.6 to 2.7) (non-inferiority not confirmed). Clinical outcome was successful in 96% and 88% of
fixed versus variable dose, respectively, with a risk difference of 8.3% (90% CI: 2.7-13.9; non-
inferiority confirmed).  
Conclusions
Although a lower fixed prothrombin complex concentrate dose was associated with successful
clinical outcome, fewer patients reached the target International Normalized Rate.
Key words: anticoagulation, hemorrhage, prothrombin complex concentrate, reversal, vitamin
K antagonist reversal.
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ABSTRACT
Introduction
Millions of patients receive vitamin K antagonist (VKA)
therapy worldwide. Although highly effective, risk of
bleeding is an important limitation. When a major bleed
occurs, rapid reversal of VKA is required. Despite 60 years
of experience with VKA and VKA-associated bleeding
events, their treatment is still a subject of debate. Either
fresh frozen plasma (FFP) or prothrombin complex con-
centrate (PCC) are infused to administer the depleted
coagulation factors.
Based on studies showing that PCC reverses VKA ther-
apy more rapidly and more completely than a standard
dose of FFP,1 several expert consensus panels have recom-
mended the use of PCC.2-4 Unfortunately, an optimal dos-
ing strategy for PCC has not been established, and
whether or not a low fixed dose can be applied is still
under discussion.5-7
Furthermore, lingering perceptions regarding the throm-
botic risk associated with PCC products in hemophiliacs,
in addition to limited licensing of PCC products for VKA
reversal, have stopped clinicians in many countries from
using PCC for this purpose.8-10
Although PCC treatment for VKA reversal in bleeding
patients is different from PCC treatment in hemophiliacs
with respect to dosing frequency, the lowest possible dose
should still be considered.
In a pilot setting, we showed a promising effect of a
low fixed dose of 1,040 IU F IX to rapidly counteract
VKA therapy.11 In this study, a trend was observed
towards a marginally lower proportion of patients who
reached the target International Normalized Rate (INR)
after treatment with the fixed dose regimen compared to
variable doses. Variable dosing is recommended by the
manufacturer and is based on patient weight, baseline
INR, and target INR. In the pilot study, results on clinical
outcome were comparable. The present prospective
study was, therefore, carried out to formally assess the
non-inferiority of the low fixed dose regimen of 1,040 IU
FIX versus the variable dose regimen of PCC for VKA
reversal in bleeding patients.
Design and Methods
Study design
This prospective, observational two-cohort study compares the
outcome of treatment with PCC for VKA reversal according to
two different dosing strategies in two Dutch teaching hospitals.
Both hospitals are located close to each other in one Dutch city.
These hospitals are comparable regarding total number of beds,
the size of the Emergency Department, Intensive Care Unit (ICU),
and Traumatology, Surgery, and Internal Medicine Departments. 
Patients 
Patients were eligible for inclusion if reversal of VKA treatment
with PCC was indicated for major or clinically relevant, non-
intracranial bleeding. Patients with an indication for PCC because
of an intracranial bleeding event, an urgent invasive procedure,
and patients not using VKA treated with PCC were excluded.
Prothrombin complex concentrate regimen
Both participating hospitals used Cofact (Sanquin BV,
Amsterdam, The Netherlands) as PCC. This product contains fac-
tors II, VII, IX and X. Cofact does not contain either activated fac-
tors or heparin. Stocks of this product were adequate and prompt-
ly available in both hospitals.
The participating hospitals applied different PCC dosing strate-
gies in routine clinical practice. Patients entering one hospital were
treated with a low fixed dose of 1,040 IU F IX. The other hospital
applied a variable dose regimen (Online Supplementary Table S1)
based on patient body weight, the baseline INR, and target INR.
After the initial dose infusion, the attending physician evaluated
VKA reversal. It was at the discretion of the physician whether to
administer additional PCC at any moment, e.g. in case of a high
INR after treatment, deterioration in patient condition, or an ongo-
ing active bleeding event. In both cohorts, all patients received 10
mg vitamin K intravenously along with the PCC infusion.
Because both dosing strategies were part of the protocol of the
local hospital, the institutional ethics committee waived the need
for informed consent.
Study end points
The primary end point was the proportion of patients who
achieved the target INR at 15 min after PCC infusion. Target INR
was below 2.0, which is accordance with Dutch routine practice
for rapid correction of INR in non-cranial bleeding emergencies. 
The secondary end point was the proportion of patients with
successful clinical outcome as judged by the attending physician.
Successful clinical outcome was confirmed when visual bleeding
had stopped, no further decrease in hemoglobin was observed,
blood pressure was normalized, and no further PCC or blood
transfusion was given. This definition is in line with that proposed
by the International Society of Thrombosis and Haemostasis.12
Time between entry into the emergency department and start
of the PCC infusion, the reached INR after PCC infusion, and the
administered PCC dose were also analyzed. 
Finally, information regarding complications during hospitaliza-
tion was recorded. This included mortality, bleeding complica-
tions, deep vein thrombosis (DVT), pulmonary embolism (PE),
myocardial infarction (MI), and ischemic cerebrovascular events.
Data collection
In both hospitals, PCC was distributed and registered by the
hospital’s blood bank when ordered for an individual patient.
After registration, the study coordinator was immediately notified
by an automatic signal, and was able to prospectively follow the
patient from that moment on.
For the included patients, level of anticoagulation was measured
prior to and 15 min after PCC treatment. Clinical outcome was
assessed by the attending physician.
Baseline status and patients’ characteristics were evaluated
using medical chart data at admission. These included age, gender,
concomitant drug use, indication for VKA and duration of VKA
therapy, baseline INR, the site of bleeding, administration of vita-
min K, and admission to the ICU. We also evaluated patient health
status and the existence of co-morbidities based on the Charlson
Comorbidity Index13,14 and the patient’s history of bleeding com-
plications.  
In both hospitals, level of anticoagulation was assessed by INR
measurement using Stacompact© (Roche diagnostics) and
Hepatoquick© reagens (Stago) with an instrument specific ISI value
of 0.92. The INR is expressed in a number up to a value of 7.6. All
INR values above 7.6 were reported as “above 7.6” in accordance
with hospital protocol. 
Information regarding invasive and non-invasive treatment of
the bleeding other than PCC administration, time between entry
into the emergency department and PCC infusion, and complica-
tions during hospitalization was collected prospectively by daily
follow up until discharge or death.
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Statistical analysis
We hypothesized that a fixed dose regimen was non-inferior to
a variable dose regimen within a margin of 4% difference in pro-
portion to the patients reaching the target INR, presuming target
INR is achieved in 99% of the patients treated with the variable
dosing regimen.
Based on the above hypothesis, it was calculated that two equal
cohorts of 106 patients were required to achieve a power of 90%
with an alpha of 5% (one-sided). 
Non-inferiority analysis for the proportion (risk) difference was
performed using an asymptotic Wald test for non-inferiority with
the non-inferiority limit set to 4%. In this, also asymptotic Wald
confidence limits were calculated. In addition, differences
between cohorts were evaluated using Student’s t-test or Mann-
Whitney test for continuous data, depending on normality of data,
and the Fisher’s exact test for categorical data. 
Subgroup analysis was planned for patients with a baseline INR
above and below 5. 
P<0.05 (two-sided) was considered statistically significant.
Commercially available computer software (IBM® SPSS®
Statistics version 19 and Statistical Analysis System 9.2; SAS
Institute, Cary, NC, USA) was used for all analyses. 
Results
Patients’ characteristics
Consecutive patients were enrolled in both cohorts
from November 2007 to July 2010.
During this period, 101 patients were included in the
fixed dose cohort and 139 patients in the variable dose
cohort. Ten patients presented with a second bleed during
the study period and were not re-enrolled. 
Both cohorts were comparable with regard to age, gen-
der, weight, relevant co-medication, Charlson
Comorbidity Index, and the indication for VKA treatment.
In both cohorts, the VKA phenprocoumon was the most
commonly used (88% vs. 84% of patients in the fixed dose
and the variable dose cohort, respectively). The mean
duration of hospitalization, during which patients were
followed up, was six days. Main patients’ characteristics
are shown in Table 1.
Prothrombin complex concentrate treatment
The range of concentration of the vitamin K dependent
factors in PCC batches used during the period of evalua-
tion was 23-26 IU F IX, 10-14 IU F VII, 19-24 IU F II, and
18-23 IU F X mL-1; 26 IU FIX per mL was used for dose
calculation. 
The most frequent indication for PCC treatment was
gastrointestinal bleeding (57% in each cohort; P=0.73)
(Table 2). In both cohorts, the severity of bleeding compli-
cations and the additional treatment besides PCC were
highly comparable whereas no differences were observed
in transfusion of red blood cells and FFP, endoscopic treat-
ment of the gastrointestinal bleeding, performance of any
other surgery to stop non-gastrointestinal bleedings, and
ICU admissions (Table 2). 
Dosage used in the fixed dose cohort was 1,040 IU F IX
and non-adherence to this dosage occurred in 32 (32%)
patients. Of these, 29 patients had a lower dose than the
fixed dose, with a median of 520 IE, and 3 patients
received a higher dose (n=1, 1,300 IE; n= 2, 1,560 IE).
In the variable dosing regimen, the median PCC dosage
per patient was 1,560 IU F IX (range 520-523,120 IU F IX;
P<0.001) (Figure 1). In the fixed dose cohort, a second PCC
infusion was required in 3 (3.0%) patients versus 4 (2.9%)
patients in the variable dose regimen cohort (P=1.00).
International Normalized Rate
Target INR was achieved in 91.7% versus 94.7% of
Table 1. Patients’ characteristic.
                                                            Fixed dose         Variable dose P value
                                                              (n=101)              (n=139)
Male, N (%)                                                    50 (50%)                 71 (51%) 0.90 
Age in years, median (range)                   77 [37-95]              79 [23-98] 0.18
Weight in kg, median (range)                  72 [36-136]            75 [43-154] 0.80
VKA is phenprocoumon, N (%)                 89 (88%)                117 (84%) 0.46
Malignancy, N (%)                                         31 (31%)                 37 (27%) 0.56
Concomitant other antithrombotic           22 (22%)                 34 (24%) 0.65 
agents, N (%)
Charlson Comorbidity Index (SD)           2.93 (2.1)                2.71 (1.7) 0.49
Indication for VKA therapy, N (%)                                                      0.71
- Atrial fibrillation                                       57 (56%)                 84 (60%)
- Venous thromboembolism                    20 (20%)                 19 (14%)
- Heart valve replacement                          9 (9%)                   17(12%)
- Myocardial infarction                                 7 (7%)                     9 (6%)
- Other                                                             8 (8%)                    10 (7%)
Time since start VKA < 3 months, N (%)12 (12%)                24 (17%) 0.28 
History of bleeding, N (%)                          26 (26%)                 46 (33%) 0.25
Baseline INR, median (range)            5.1 [1.54- >7.6]     5.9 [1.80- >7.6] 0.76
- Baseline INR >7.6 N (%)                        35 (35%)                 49 (35%) 1.0 
ICU admissions at entry, N (%)                12 (12%)                  12 (9%) 0.51
VKA, Vitamin K antagonists; INR, International Normalized Ratio; ICU, Intensive Care Unit.
Acenocoumarol was the only VKA used besides phenprocoumon. Concomitant antithrombotic
drugs: acetyl salicylic acid, clopidogrel, non-steroid anti-inflammatory drugs, and low molecular
weight heparins.
Table 2. Indication for PCC treatment and concomitant therapy.
Fixed dose Variable dose P value
(n=101) (n=139)
Indication for PCC treatment, N (%) 0.73
- Gastrointestinal bleed 58 (57%) 79 (57%)
- Muscle bleed 9 (9%) 17 (12%)
- Intraperitoneal or abdominal 10 (10%) 8 (6%)
wall bleed
- Hemoptysis 4 (4%) 5 (4%)
- Other 20 (20%) 30 (22%)
Endoscopic treatment of total GI 27 (47%) 33 (42%) 0.60
bleeding complications, N (%)
Invasive procedure for all non-GI 15 (35%) 20 (34%) 1.00
bleeding complications, N (%)
Use of hemostatic drugs, N (%) 10 (10%) 6 (4%) 0.12
Transfusion of RBC, N (%) 62 (62%) 92 (66%) 0.50
Transfusion of FFP, N (%) 15 (15%) 12 (9%) 0.15
Mortality during hospitalization 14 (14%) 36 (26%) 0.025
Other indications for PCC treatment were: anemia and hemoglobin decrease in unstable patient (5
fixed dose, 8 variable dose), severe epitaxis (1 fixed dose versus 6 variable dose), bleeding compli-
cations at the surgery site (4 fixed dose vs. 6 variable dose), severe haematuria (1 fixed dose vs. 2
variable dose), multiple bleeds after a fall (2 fixed dose, 1 variable dose), hematothorax (1 in each
cohort), severe vaginal bleeding (2 fixed dose vs. 1 variable dose), leaking dialysis shunt (2 fixed
dose), kidney bleed (1 fixed dose), sigmoid perforation (1 fixed dose), ruptured aneurysm (3 vari-
able dose), hemartosis (1 variable dose), and intraoculair bleed (1 variable dose). Hemostatic
drugs consisted of: desmopressin, protamin, and tranxamic acid. Activated factor VII was not used
in either cohort. RBC: red blood cells; FFP: fresh frozen plasma.
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patients in the fixed dose and the variable dose cohorts,
respectively, resulting in a risk difference of -2.99% (90%
CI: -8.64 to 2.66) for non-inferiority with the limit set to
4%, indicating that non-inferiority was not established
(Table 3).   
In the fixed dose cohort, median INR declined from 5.1
(range 1.5 to above 7.6) at baseline to 1.5 (range 1 to 2.9)
and in the variable dose cohort, from 5.9 (range 1.8 to
above 7.6) to 1.4 (range 0.9 to 3.4), after PCC treatment
(Figure 2).
Furthermore, the results on the planned subgroup analy-
sis of baseline INR below 5 showed that non-inferiority
was established for the subgroup of patients with a base-
line INR below 5 (risk difference 1.9%, 90% CI: -1.2 to
5.1; P<0.001). 
An additional post hoc analysis showed that non-inferior-
ity of the fixed dose was reached in all patients with a
baseline INR below 7.5; this was 64% of the total popula-
tion (risk difference 1.9%, 90% CI: -2.4 to 6.1; P<0.01). 
Data were also analyzed applying a reached INR of less
than 1.5, which is often used internationally. This target
INR was reached by 51% of patients in the fixed dose
cohort and 62% of patients in the variable dose cohort.
The results of the baseline INR analyses and the target
INR differentiation are reported in Table 4.
Clinical outcome 
Successful clinical outcome was seen in 97 of 101 (96%)
patients in the fixed dose cohort versus 122 of 139 (88%)
in the variable dose cohort, with a risk difference of 5.8%
(P< 0.001). This indicates non-inferiority of the fixed dose
versus the variable dose in the overall data, independently
of the reached INR (Table 3).
Prothrombin complex concentrate dose in relation
to body weight and clinical outcome
Regarding PCC dose expressed in units F IX per kilo-
gram body weight and clinical outcome, no significant dif-
ferences were seen between the dosage infused to patients
with a positive clinical outcome versus patients with a neg-
ative clinical outcome within each cohort. In the fixed
dose cohort, patients with a positive clinical outcome
were treated with a median of 13.2 IU F IX/kg (range 2.9-
28.9) versus 14.1 IU F IX/kg (range 8.7-15.5) in those treat-
ed in the same cohort with a negative clinical outcome
(P=0.73).
In the variable dose cohort, patients with a positive clin-
ical outcome were treated with a median of 21.0 IU F
IX/kg (range 8.2-40.0) versus 18.8 IU F IX/kg (range 13.0-
35.5) in those treated in the same cohort with a negative
clinical outcome (P=0.95).
Interestingly, no significant differences were observed in
body weight between both cohorts (Table 1).
Time to infusion
Time from hospital admission to infusion was recorded
for all patients for whom PCC was ordered in the emer-
gency department, which was 60% of our population. In
the fixed dose cohort, median time to infusion was 130
min (90% central range 22-233), whereas in the variable
dose regimen cohort, the median time to infusion was 160
min (90% central range 60-320; P=0.015).
Complications 
One patient in the variable dose regimen developed a
deep venous thrombosis, and one patient died in each
cohort because of a thromboembolic complication; overall
occurrence of thrombotic complications was 1.3%. 
Overall mortality rate during hospitalization was 14 of
N. Khorsand et al.
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Figure 1. INR before and after PCC treatment. Cohort 1: fixed dose,
cohort 2: variable dose regimen. International Normalized Ratio
(INR) at baseline and 15 min after PCC treatment. INRs are
expressed as a number up to 7.6. INR was above 7.6 in 35% of
patients in each cohort. Boxes span the interquartile range.
Horizontal lines bisecting the boxes indicate median values and
lower and upper error bars the range. 
Figure 2. PCC administration. Prothrombin Complex Concentrate
(PCC) administered per patient. Graphic conventions as in figure 1.
In cohort 1, median dosage is the same line as upper interquartile
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101 (14%) in the fixed dose cohort versus 36 of 139 (26%)
in the variable dose regimen  (P=0.025).
An ongoing bleeding event was fatal in 2 of 14 (14%)
patients in the fixed dose cohort and 8 of 36 (22%) in the
variable dose cohort (P=0.70).
Discussion
This prospective, observational two-cohort study, com-
paring the treatment outcome of a low fixed PCC dosing
regimen of 1,040 IU F IX with the variable PCC dose strat-
egy to rapidly counteract VKA therapy showed that target
INR is reached in fewer patients treated with fixed PCC
dose (92%) compared to the variable dose regimen (95%),
indicating that non-inferiority was not established. In
terms of successful clinical outcome, non-inferiority of the
fixed dose strategy was established (96% in fixed dose vs.
88% in variable dose regimen), independently of the INR.
While the non-inferiority of the low fixed dose is
assessed in terms of clinical outcome, independently of
the initial INR and the reached INR, we also performed a
planned subgroup analysis and a post hoc analysis to gain a
better understanding of the role and contribution of the
baseline INR to clinical outcome.
These analyses showed that the inferiority of the low
fixed dose is entirely applicable for those patients with a
baseline INR above 7.5. For all patients presenting with a
baseline INR up to 7.5, non-inferiority of the low fixed
dose for both reaching the target INR as well as clinical
outcome is confirmed. Two-thirds of our population pre-
sented with a baseline INR below 7.5. 
The target INR used in our study is in line with Dutch
common practice for non-cranial bleeding emergencies.
From an international point of view, it is interesting to
know the proportion of patients reaching an INR below
1.5. Therefore, we also considered an analysis that
showed that the INR decreases more often below 1.5 with
higher doses in the variable dose cohort (Table 4). 
Considering the thromboembolic events after PCC treat-
ment, our study showed a very low occurrence of throm-
boembolic complications in both cohorts (overall 1.2%).
Our findings are comparable with other studies in VKA
using patients receiving PCC in which thrombotic events
were also reported to be rare but still quantifiable.15-20
In the present study, we measured the time to start PCC
infusion on patients who were treated with PCC in the
emergency department. Our data show a shorter time to
infusion, with a median of 30 min, in the low fixed PCC
dose regimen. As there was no difference in the availabil-
ity of PCC or in logistical procedures between the two
hospitals, this was probably due to the fact that applying
a fixed dose resulted in a shorter time to infusion. This
reduction in time could explain our paradoxical results for
INR and clinical outcome. It suggests that the critical fac-
tor for successful clinical outcome is time to infusion
rather than baseline INR. However, this is the first time
this phenomenon has been observed and our finding
must, therefore, be confirmed in future research, prefer-
ably in a randomized setting.
Obviously, the non-randomized design of the study and
differences in care and patient population between both
participating hospitals are major limitations, and a selec-
tion bias cannot be excluded. We thoroughly evaluated
possible differences between both cohorts, as shown in
Tables 1 and 2. Analyzing the health status (Charlson
Comorbidity Index and history of bleeding events) of
patients in both cohorts showed a trend towards more
patients in the variable dose cohort having a history of
bleeding events, although this was not statistically signifi-
cant. This difference between both cohorts could have
contributed to the lower proportion of patients with a suc-
cessful clinical outcome and a higher mortality in the vari-
able dosing regimen cohort although, again, this was not
statistically significant. All other patients’ characteristics
were found to be comparable. To prevent misclassification
of outcomes, we defined a priori successful clinical outcome
using the same objective criteria in both hospitals.
Interestingly, we saw the same trend in difference in mor-
tality rate in our previous pilot study which was performed
in one Dutch hospital site when switching from the vari-
able dose regimen to a low fixed dose regime.11 While
bleeding was not a direct cause of death in the majority of
patients, it could have a potential prognostic implication as
a predictor of poor outcome in clinical assessments. An in
depth study has been made of bleeding complications
after, for example, bone marrow transplantation.21
Because of the observational design of our study, our
patient population represents daily clinical practice in an
emergency setting. This also includes non-adherence to
Table 3. Overall results.
Fixed dose Variable dose Proportion
(n=101) (n=139) difference or
P value
Target INR reached, N (%) 88 (91.7%) 124 (94.7%) -2.99% 
(90 % CI: -8.6 - 2.7)
Successful clinical outcome, N (%) 97 (96%) 122 (88%) 8.27 %
(90 % CI: 2.7 - 13.9)
PCC dosage in F IX/patient, 1040 IU 1560 IU **P<0.001
median [range] [260-1560] [520-3120]
INR after PCC treatment, 1.48 1.40 *P=0.018
median [range] [1-2.94] [0.9-3.40]
Time to infusion in minutes, median 130 160 *P=0.015
[90% central range] [22-233] [60-320]
The INR after PCC treatment is missing in 5 (5.0%) patients in the fixed dose cohort and 8 (5.6%)
in the variable dose regimen. 
Table 4. Results on INR.
                                                            Fixed dose                      Variable dose
                                                               (n=96)                             (n=131)
Target INR < 2.0 reached, N (%)                 88 (91.7%)                             124 (94.7%)
Baseline INR > 7.5, N                                             35                                              45
- Target INR reached, N (%)                        28 (80%)                                 41 (91%)
Baseline INR 5.0-7.5, N                                           15                                             34
- Target INR reached, N (%)                        14 (93%)                                 32 (94%)
Baseline INR < 5.0, N                                             46                                              52
- Target INR reached, N (%)                       46 (100%)                                51 (98%)
                                                                                   
Reached INR                                                                                                                
- Reached INR < 1.5, N (%)                         49 (51%)                                 81 (62%)
- Reached INR 1.5 - 2.0, N (%)                     39 (41%)                                 43 (33%)
- Reached INR > 2.0, N (%)                           8 (8%)                                     7 (5%)
The INR after PCC treatment is missing in 5 (5.0%) patients in the fixed dose cohort and 8 (5.6%)
in the variable dose regimen. 
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the dosage, as according to hospital protocols. This is illus-
trated by the range of the median PCC dosage, especially
in the fixed dose cohort. Since the aim of the study was to
analyze daily clinical practice, we included all patients
treated with PCC despite the abovementioned non-adher-
ence. Importantly, in the fixed dose cohort, non-adherence
resulted in the vast majority of patients being adminis-
tered lower PCC doses than the indicated 1,040 IE F IX
(median 520 IU F IX). Non-adherence, therefore, did not
exert a favorable influence on the results for the fixed PCC
dose over the variable dose.
Despite 60 years of experience, there is still considerable
heterogeneity in consensus guidelines for the treatment of
VKA-associated bleeding. Given the lack of evidence for
adequate dosing strategies, a delayed start of treatment is
being considered in the critical care setting. Even though
new oral anticoagulants are entering routine clinical prac-
tice, it is likely that VKA and PCC will still be used exten-
sively over the next few years (and possibly longer).
Therefore, the need for well-defined strategies for emer-
gent PCC therapy is still relevant,22 particularly since PCC
may be used as an antidote for some of the new oral anti-
coagulants.23
Although the low fixed dose is inferior in reaching the
target INR in patients with a baseline INR above 7.5, we
advocate immediate treatment of all patients entering the
emergency department with a major or clinically relevant
VKA-associated non-intracranial bleeding event with a
low fixed dose of 1,040 IU F IX. This speeds up the treat-
ment procedure and is non-inferior with regard to success-
ful clinical outcome compared with the variable PCC
dose. An additional PCC dose can be considered as soon
as the baseline INR measurement has been reported.
Conclusions
The non-inferiority of the fixed PCC dose of 1,040 IU F
IX based on the proportion of patients reaching the target
INR of less than 2 has not been established. Regarding suc-
cessful clinical outcome, non-inferiority of the fixed dose
strategy has been established independently of baseline
INR for all patients, with time to start PCC infusion short-
ened by a median of 30 min.
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